Kashiv Biosciences has agreed to be acquired by Amneal Pharmaceuticals, aiming to create a fully integrated global leader in biosimilars.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The transaction will integrate both parties’ advantageous resources in R&D, production, and commercialization to form a strong synergy. Through this strategic merger, the new entity will possess capabilities spanning the entire value chain of biosimilars—from early-stage development to global marketing—further strengthening its competitiveness in the rapidly growing biopharmaceutical market. Market observers believe this integration will reshape the industry landscape and provide patients with more affordable, high-quality treatment options. The financial details and specific timeline of the transaction have not yet been disclosed, and completion is expected after the customary closing conditions are met. Both management teams are optimistic about the merged entity’s prospects, believing this will accelerate access to innovative therapies and create long-term sustainable value.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia (NVDA.US) further strengthens AI infrastructure by investing $2 billion in Brookfield (BAM.US) Global AI Fund, which aims to raise $10 billion.
Nvidia has invested $2 billion in the Global Artificial Intelligence Infrastructure Fund under Brookfield Asset Management.
智通财经•2026/09/17 22:26
LCNB Chief Wealth Officer Michael Miller to Retire
MT newswire•2026/09/17 21:53
Loop Industries to Evaluate Alternatives, India Joint Venture Financing
MT newswire•2026/09/17 21:28
